Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 9,443 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Activity Clear all
Completed Phase 1 Interventional

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

NCT02367183
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional

Group-based Chronic Kidney Disease Care

NCT02467894
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Group-based Care
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

NCT01476137
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 23, 2026, 8:13 PM EDT
Suspended Phase 2 Interventional

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

NCT00065572
View directory record Official record
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms
Interventions
ZD6126, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Los Angeles, California • Newark, Delaware • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 23, 2026, 8:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT03958877
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIIB017 (peginterferon beta-1a), Interferon beta type 1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional

The Watch the Spot Trial

NCT02623712
View directory record Official record
Conditions
Solitary Pulmonary Nodule, Coin Lesion, Pulmonary, Lung Neoplasms, Carcinoma, Non-small-cell Lung
Interventions
More Frequent Surveillance Strategy, Less Frequent Surveillance Strategy
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
35 Years and older
Enrollment
34,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens

NCT05927753
View directory record Official record
Conditions
Refractive Error - Myopia Bilateral
Interventions
Deseyne Daily Disposable Contact Lens (Test Device)
Device
Lead sponsor
Bruno Vision Care
Industry
Eligibility
18 Years to 40 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Longwood, Florida • Pittsburg, Kansas • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 8:13 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT03596645
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab, Infliximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
View directory record Official record
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 23, 2026, 8:13 PM EDT
Recruiting Phase 2 Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
29
States / cities
Berkeley, California • Duarte, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strong Families Strong Forces: Supporting Active Duty Families With Very Young Children

NCT03045159
View directory record Official record
Conditions
Deployment
Interventions
Strong Families Strong Forces, Strong Parents
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional Results available

Walk On! Physical Activity Coaching

NCT02478359
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Physical Activity Coaching (Walk On!)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
41 Years and older
Enrollment
2,707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 23, 2026, 8:13 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteers

NCT06484088
View directory record Official record
Conditions
Irritability
Interventions
Frustration task
Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional

ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit

NCT01270269
View directory record Official record
Conditions
Brain Injuries, Dementia, Myopathies, Muscle Disorders
Interventions
Behavioral: Physical and functional rehabilitation, Behavioral: Cognitive, physical, & functional rehabilitation
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Scalable, IVR-supported Cancer Prevention Interventions in the Rural Alabama Black Belt

NCT03903874
View directory record Official record
Conditions
Physical Activity
Interventions
Deep south Interactive voice response system supported Active Lifestyle (DIAL)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 23, 2026, 8:13 PM EDT
Completed No phase listed Observational

Pediatric Facial Fracture Study

NCT00759486
View directory record Official record
Conditions
Craniofacial Fracture
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 23, 2026, 8:13 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I
Interventions
Furmonertinib
Drug
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Prescott, Arizona • Sacramento, California • Whittier, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 23, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

NCT00447473
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, Ketoconazole, Mitoxantrone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 23, 2026, 8:13 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Skin Sympathetic Nerve Activity and Cardiac Arrhythmias

NCT02939469
View directory record Official record
Conditions
Sympathetic Nerve Activity
Interventions
Physiologic maneuvers
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 23, 2026, 8:13 PM EDT
Completed Phase 1Phase 2 Interventional

Antihyperlipidemic Effects of Oyster Mushrooms

NCT00069524
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
oyster mushroom
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Oct 23, 2026, 8:13 PM EDT